Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry.
Rossella MarcucciGiuseppe PattiPaolo CalabròAnna Maria GoriGuido GrossiPlinio CirilloVittorio PengoPaolo GreselePasquale PignatelliEmilia AntonucciCarlo di MarioSerafina ValenteGualtiero PalaretiPublished in: PloS one (2019)
The analysis of the register has documented that both ticagrelor and prasugrel are associated with a statistically significant reduced total and cardiovascular mortality but both do not show a significant increased incidence of major and minor bleedings with respect to clopidogrel.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- end stage renal disease
- newly diagnosed
- risk factors
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- electronic health record
- prognostic factors
- coronary artery disease
- type diabetes
- atrial fibrillation
- patient reported
- replacement therapy